Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision
1. H.C. Wainwright rates OMER as Buy with a $9 price target. 2. Omeros approaches FDA decision on Narsoplimab expected September 25. 3. Narsoplimab's approval could unlock $500-$1B commercial opportunity. 4. Omeros is scaling back other initiatives to focus on Narsoplimab launch. 5. Despite past losses, OMER shares are trending up by 3.58%.